Overview
Globally recognized as the premier source of clinical, basic, and translational research on stem cells of all tissue types and their potential therapeutic applications.
Founded by Mary Ann Liebert in 1980, Mary Ann Liebert, Inc. is a leading independent publisher of scientific, technical, and medical content, known worldwide for its prescience and establishment of authoritative peer-reviewed journals, books, and trade publications in cutting-edge fields such as biotechnology, biomedical research, medicine and surgery, public health research and policy, technology and engineering, law, environmental research and policy, and other specialized disciplines. The company publishes over 90 peer-reviewed journals, leading trade magazines, and specialized newsletters, in addition to society membership management and conferences.
Driven by her visionary passion and ceaseless curiosity, Mary Ann Liebert identifies and nurtures critical topics and cutting-edge fields by creating first-to-market, specialized publications that play a vital role in advancing research and facilitating collaboration in academia, industry, and government. The company is deeply committed to ensuring the highest quality content and is able to invest for the long-term, supporting publications in emerging markets through to maturity.
The company’s flagship publication, Genetic Engineering & Biotechnology News (GEN), was launched in 1980, the very first publication of its kind for the field of biotechnology. Today, GEN is the most widely read and highly regarded publication in the field, delivering cutting-edge news and analysis of the technologies, applications, and trends that are driving the future of biotechnology. GEN has been at the forefront of the field since the birth of biotech, maintaining unrivaled integrity, influence, and expertise that plays a pivotal role in driving the productivity and growth of the industry.
Reviews are disabled, but trackbacks and pingbacks are open.